# Centene (CNC) Financial Model Free Excel 3-statement financial model and company analysis for Centene. - Canonical: https://finamodel.com/companies/centene - Industry: Health Insurance - Downloadable model: Yes - Excel download: https://finamodel.com/company-models/CNC.xlsx ## Model Purpose This model evaluates the equity valuation and earnings power of Centene Corporation, allowing an equity analyst to forecast the normalisation of the Health Benefits Ratio (HBR) post-Medicaid redeterminations, assess the margin impact of the Value Creation Plan, and project membership growth across government-sponsored healthcare segments. ## Company Overview Centene Corporation is a leading managed care organisation (MCO) focused primarily on government-sponsored healthcare programmes, serving uninsured and under-insured individuals. The company operates as a health insurer, collecting premiums from states and the federal government to manage the healthcare costs of its members. - **Business segments:** Medicaid (approx. 55% of premium revenues), Commercial/Marketplace (approx. 25%), and Medicare (approx. 20%). - **Key geographies:** United States (national footprint with significant state-level contracts in Florida, Texas, California, and Michigan). - **Business model type:** Asset-light managed care / insurance model. - **Competitive position:** The largest Medicaid managed care organisation in the US and the largest provider of Health Insurance Marketplace (Ambetter) products. Key competitors include UnitedHealth Group, Elevance Health, Molina Healthcare, and CVS Health (Aetna). - **Recent major events:** The unwinding of the COVID-19 Public Health Emergency (PHE) led to significant Medicaid redeterminations in 2023-2024, reducing Medicaid membership by over 3 million while temporarily spiking acuity and the Medicaid HBR. The company has also been executing its "Value Creation Plan," which involves divesting non-core assets (Magellan Rx, Pantherx, Circle Health), rationalising real estate, and transitioning its PBM contract to Express Scripts in 2024. ## Revenue Deep Dive ### Medicaid - **Segment name:** Medicaid - **Revenue driver formula:** Average Medicaid Members x Medicaid Premium per Member per Month (PMPM) - **Historical growth rate:** 5-8% CAGR historically, but experienced a contraction in 2024 due to PHE unwinding. - **Key growth levers and headwinds:** Headwinds from state redeterminations removing ineligible members; tailwinds from state rate increases designed to match the higher acuity of the remaining member pool, plus new state contract wins/expansions. - **Pricing dynamics:** Regulated and contractual. States set capitation rates annually based on actuarial data. - **Revenue recognition notes:** Recognised ratably over the period of coverage. State pass-through payments are recorded as premium revenue with an offsetting 100% medical cost. - **Seasonality:** Relatively stable, though rate updates typically occur on 1 January or 1 July depending on the state's fiscal year. ### Commercial - **Segment name:** Commercial (primarily Health Insurance Marketplace / Ambetter) - **Revenue driver formula:** Average Commercial Members x Commercial PMPM - **Historical growth rate:** 15-25% recent CAGR (membership grew 12% in 2024 alone). - **Key growth levers and headwinds:** Driven by ACA subsidy extensions, geographic expansion into new counties, and strong product positioning. - **Pricing dynamics:** Competitive bidding on state exchanges, heavily influenced by federal subsidies (Advance Premium Tax Credits). - **Revenue recognition notes:** Includes risk adjustment estimates which can be trued up in subsequent quarters. - **Seasonality:** Q1 sees the highest influx of new members following the Open Enrollment Period. ### Medicare - **Segment name:** Medicare (Medicare Advantage and Prescription Drug Plans - PDP) - **Revenue driver formula:** Average Medicare Members x Medicare PMPM - **Historical growth rate:** 5-10% CAGR. - **Key growth levers and headwinds:** Headwinds from recent Medicare Advantage Star Ratings downgrades impacting bonus payments; tailwinds from strong PDP enrolment and demographic shifts (ageing population). - **Pricing dynamics:** Regulated by CMS; heavily dependent on Star Ratings and risk coding (hierarchical condition categories). - **Revenue recognition notes:** Subject to CMS risk adjustment retroactivity. - **Seasonality:** Q1 enrolment spikes; Q4 often sees higher Premium Deficiency Reserve (PDR) adjustments. ## Cost Structure ### Variable Costs / COGS - **Line-by-line breakdown:** Medical Costs (claims paid to providers, pharmacy costs, capitation payments to medical groups). - **Gross margin range:** Evaluated inversely via the Health Benefits Ratio (HBR). Consolidated HBR ranges from 87.0% to 89.6% (Gross Margin of 10.4% to 13.0%). - **Key input costs and commodity exposures:** Hospital unit costs, physician fee schedules, prescription drug prices (managed via Express Scripts PBM). - **How COGS scales with revenue:** Highly linear. Medical costs scale directly with membership and acuity. ### Operating Expenses - **R&D:** Not applicable / not reported. - **SG&A:** Selling, General & Administrative Expenses. Includes broker commissions, marketing, claims processing, and corporate overhead. Target ratio is 8.0% to 9.0% of revenues (8.5% in 2024). Driven by headcount, IT infrastructure, and marketing spend. - **Depreciation & Amortisation:** Typically 1.0% to 1.5% of revenue, heavily weighted towards amortisation of acquired intangible assets from historical M&A (WellCare). - **Stock-Based Compensation:** Typically 0.2% to 0.3% of revenue. - **Restructuring / one-time charges:** Frequent in recent years due to the Value Creation Plan (real estate impairments, severance, divestiture losses). ### Margin Profile - **Gross margin:** 10.4% - 13.0% (inverse of HBR). - **EBITDA margin:** 4.5% - 5.5%. - **Operating margin:** 3.0% - 4.0%. - **Net margin:** 1.5% - 2.5%. - **Margin trend:** Expanding at the SG&A line due to the Value Creation Plan, but gross margins have faced temporary compression due to Medicaid redeterminations (Medicaid HBR spiked to 92.5% in 2024). ## Balance Sheet Structure - **Total assets:** Approximately $75 billion to $80 billion. - **Key asset categories:** Cash and cash equivalents, Investments (regulated statutory capital held at the subsidiary level), Premium and related receivables, Goodwill and Intangible Assets. - **Goodwill & intangibles as % of total assets:** High (approx. 35-40%) due to the $17 billion acquisition of WellCare in 2020 and Magellan Health in 2022. - **Working capital profile:** - **Days Sales Outstanding (DSO):** 15-25 days (state and federal payers are generally prompt, though state budget delays can cause spikes). - **Days Inventory Outstanding (DIO):** N/A. - **Days in Claims Payable (DCP):** 40-50 days. This is the critical working capital metric for MCOs. - **Net working capital as % of revenue:** Typically negative. - **Is working capital positive or negative?** Negative. The company collects premiums upfront and pays medical claims later, generating a structural cash flow advantage (float). - **PP&E:** Minimal (approx. 2-3% of assets). Consists of corporate real estate and IT hardware. - **Right-of-use assets / operating leases:** Material but shrinking as the company rationalises real estate under the Value Creation Plan. ## Capital Expenditure & Investment - **Capex as % of revenue:** 0.5% - 1.0%. - **Maintenance capex vs. growth capex:** Predominantly growth/IT capex (capitalised software for claims processing and digital member platforms). - **Major capex programmes underway or planned:** Investments in AI for prior authorisation and integration of core administrative processing systems. - **Capitalised software / development costs if material:** Highly material; forms the bulk of additions to PP&E. - **M&A pattern:** Historically a transformational acquirer (Health Net, WellCare, Magellan), but currently in a divestiture and organic growth phase. - **Typical acquisition multiple paid:** Historically 12-15x forward P/E for managed care assets. ## Debt & Capital Structure - **Total debt:** Approximately $17 billion to $18 billion. - **Debt/EBITDA ratio:** Managed to a target of approximately 2.9x to 3.0x. - **Credit rating:** Ba1 (Moody's) / BBB- (Fitch) / BBB- (S&P) - crossover/low investment grade. - **Key debt instruments:** Senior unsecured notes (bonds) and a revolving credit facility. - **Maturity profile:** Well-laddered with average maturity of 5-7 years. - **Interest rate profile:** Predominantly fixed-rate senior notes. - **Covenants:** Standard maximum leverage and minimum interest coverage ratios. - **Share repurchase programme:** Highly active. Executed $3.0 billion in 2024. - **Dividend policy:** The company does not currently pay a dividend, prioritising share repurchases and debt paydown. ## Cash Flow Characteristics - **Operating cash flow conversion:** Highly variable year-to-year due to the timing of state payments and pharmacy rebates, but averages 1.2x to 1.5x Net Income over a multi-year period. - **Free cash flow margin:** 2.0% - 3.0%. - **Major non-cash items that bridge net income to OCF:** Depreciation & amortisation, deferred income taxes, and changes in medical claims liability. - **Working capital cash flow impact:** Growth in medical costs naturally generates operating cash flow due to the lag in claims payment (increasing the medical claims liability). - **Capex intensity:** Very low. - **Cash tax rate vs. GAAP effective tax rate:** Cash taxes are generally lower than GAAP taxes due to accelerated depreciation and amortisation of intangibles. ## Sheet Structure 1. **Assumptions:** Hardcoded drivers for membership, PMPM, HBR by segment, SG&A ratio, and capital deployment. 2. **Summary:** Dashboard showing EPS, consolidated HBR, total membership, and valuation outputs. 3. **Membership & Revenue:** Roll-forward of members (Beginning + Adds - Terms = Ending) and calculation of Premium Revenue by segment (Medicaid, Commercial, Medicare). 4. **Medical Costs:** Calculation of medical expenses using segment-specific HBRs applied to segment premium revenues. 5. **Operating Expenses:** SG&A (driven by % of revenue), Premium Taxes (pass-through), and D&A schedules. 6. **Income Statement:** Consolidated GAAP and Adjusted P&L (excluding divestiture impacts and amortisation of acquired intangibles). 7. **Working Capital:** Schedule driving Premium Receivables (DSO) and Medical Claims Liability (DCP). 8. **Balance Sheet:** Standard balancing statement with breakout of statutory vs. unregulated cash. 9. **Cash Flow Statement:** Indirect method, highlighting the change in Medical Claims Liability. 10. **Debt Schedule:** Tranches of senior notes, interest expense calculation, and share repurchase tracking. 11. **DCF Valuation:** Unlevered free cash flow calculation, WACC, and terminal value. ## Key Financial Relationships 1. `Average Membership = (Beginning Membership + Ending Membership) / 2` 2. `Segment Premium Revenue = Average Segment Membership x Segment PMPM x 12` 3. `Total Premium and Service Revenue = Medicaid Revenue + Commercial Revenue + Medicare Revenue + Service Revenue` 4. `Segment Medical Costs = Segment Premium Revenue x Segment HBR` 5. `Consolidated Medical Costs = Sum of Segment Medical Costs` 6. `Consolidated HBR = Consolidated Medical Costs / Total Premium Revenue` 7. `SG&A Expense = Total Revenues x SG&A Expense Ratio` 8. `Medical Claims Liability = (Consolidated Medical Costs / 365) x Days in Claims Payable (DCP)` 9. `Premium Receivables = (Total Premium Revenue / 365) x Days Sales Outstanding (DSO)` 10. `Adjusted Net Income = GAAP Net Income + Amortisation of Acquired Intangibles (net of tax) + Restructuring/Divestiture Charges (net of tax)` 11. `Adjusted EPS = Adjusted Net Income / Diluted Shares Outstanding` 12. `Ending Shares Outstanding = Beginning Shares - (Share Repurchase Amount / Average Share Price)` ## Cross-Sheet Dependencies - **Membership & Revenue** feeds **Medical Costs** (to calculate claims) and the **Income Statement** (top line). - **Medical Costs** feeds the **Income Statement** and the **Working Capital** sheet (to calculate the Medical Claims Liability balance). - **Working Capital** feeds the **Balance Sheet** and the **Cash Flow Statement** (changes in working capital). - **Cash Flow Statement** feeds the **Debt Schedule** (cash available for share repurchases) and the **Balance Sheet** (ending cash). - **Debt Schedule** feeds the **Income Statement** (interest expense) and the **Balance Sheet** (debt balances). - Circularity risk exists between the **Debt Schedule** (interest expense), **Income Statement** (net income), **Cash Flow Statement** (cash generated), and **Debt Schedule** (debt paydown/repurchases). A circuit breaker toggle must be included. ## Sign Convention - **Inputs/Assumptions:** Entered as positive numbers (e.g., HBR = 88.3%, SG&A ratio = 8.5%). - **Income Statement:** Revenues are positive. Expenses (Medical Costs, SG&A, D&A) are positive in their supporting schedules but subtracted in the Income Statement to calculate operating profit. - **Cash Flow Statement:** Cash inflows are positive; cash outflows (capex, share repurchases, debt paydown) are negative. - **Balance Sheet:** Assets are positive; Liabilities and Equity are positive. ## Things Most Likely to Go Wrong 1. **Mismodelling Medicaid Redeterminations:** Failing to account for the drop in Medicaid membership while simultaneously increasing the Medicaid HBR (due to higher acuity of remaining members). 2. **Consolidated vs. Premium Revenue:** Calculating HBR against *Total Revenues* instead of *Premium Revenues*. Service revenues and investment income must be excluded from the HBR denominator. 3. **Pass-Through Premium Taxes:** Forgetting that state premium taxes are a straight pass-through. They inflate total revenue and operating expenses equally but have zero impact on operating profit. 4. **Days in Claims Payable (DCP) Errors:** Tying DCP to total operating expenses instead of strictly to Medical Costs. This will drastically miscalculate the Medical Claims Liability. 5. **Adjusted vs. GAAP EPS:** Failing to add back the amortisation of acquired intangible assets. Centene's GAAP EPS is significantly lower than its Adjusted EPS ($6.31 vs $7.17 in 2024) primarily due to WellCare intangibles. 6. **Divestiture Noise:** Projecting historical service revenue growth forward without stripping out the revenues from divested entities like Circle Health and Magellan Rx. 7. **Share Repurchase Impact:** Not reducing the diluted share count dynamically based on the $3.0B+ annual share repurchase programme, which artificially depresses forecasted EPS. 8. **Timing of State Payments:** Assuming linear operating cash flow. State payments can slip by a few days across quarter-end or year-end, causing massive swings in OCF and receivables. ## Validation Checks 1. "Consolidated HBR should remain between 87.5% and 89.5%; flag if outside this band." 2. "SG&A as a % of Total Revenues should be between 8.0% and 9.0% based on the Value Creation Plan." 3. "Days in Claims Payable (DCP) must be between 40 and 50 days; flag if working capital generates unrealistic cash flows." 4. "Debt/Adjusted EBITDA should remain near the 2.9x to 3.0x target." 5. "Balance sheet must balance: Total Assets = Total Liabilities + Equity in every period." 6. "Adjusted EPS must be higher than GAAP EPS by approximately $0.80 to $1.00 per share due to intangible amortisation." 7. "Effective tax rate on adjusted earnings should be between 20.0% and 24.0%." ## Key Assumptions (Default Values) | Assumption | Default Value | Unit | Rationale | |---|---|---|---| | Medicaid HBR | 90.5 | % | Normalising down from the elevated 92.5% in 2024 as rates match acuity post-redeterminations. | | Commercial HBR | 75.0 | % | Consistent with historical performance and strong risk adjustment execution. | | Medicare HBR | 90.0 | % | Reflects ongoing pressure from Star Ratings and elevated outpatient utilisation. | | SG&A Expense Ratio | 8.5 | % | Actual 2024 ratio, reflecting cost savings from the Value Creation Plan. | | Medicaid Membership Growth | 1.0 | % | Stabilising after the massive 2023-2024 redetermination declines. | | Commercial Membership Growth | 5.0 | % | Moderating from 12% in 2024 as the ACA market matures. | | Days in Claims Payable (DCP) | 45 | Days | Industry standard and consistent with Centene's historical average. | | Days Sales Outstanding (DSO) | 20 | Days | Based on historical premium receivable balances. | | Effective Tax Rate | 22.0 | % | Standard corporate rate adjusted for state taxes. | | Annual Share Repurchases | 3,000 | $ Millions | Matches the actual capital deployed for repurchases in 2024. | | Average Interest Rate on Debt | 4.5 | % | Weighted average cost of existing senior notes. | | WACC | 7.5 | % | Reflects low beta of managed care but incorporates current risk-free rates. | | Terminal Growth Rate | 2.0 | % | Aligns with long-term inflation and GDP growth. | ## Data Sources & Benchmarks - **Filings:** SEC EDGAR (Centene 10-K, 10-Q, 8-K earnings releases). - **Investor Relations:** Centene Investor Relations website (specifically the Q4 2024 Earnings Release and Investor Day presentations detailing the Value Creation Plan). - **Key Peers for Benchmarking:** UnitedHealth Group (UNH), Elevance Health (ELV), Molina Healthcare (MOH), CVS Health / Aetna (CVS). - **Industry Data Sources:** Centers for Medicare & Medicaid Services (CMS) for Star Ratings and Medicaid enrolment data; Kaiser Family Foundation (KFF) for state-by-state Medicaid unwinding trackers. ## Sources - Centene Corporation Q4 2024 Earnings Release (4 February 2025): https://investors.centene.com/ - Centene Corporation 2024 Form 10-K filed with the SEC. - Georgetown University Center for Children and Families: "Medicaid Managed Care: The Big Five in Q4 2024" (27 February 2025). - Centene Investor Day Presentations (Value Creation Plan details). - The Motley Fool: Centene (CNC) Q4 2024 Earnings Call Transcript. --- ## Frequently asked questions ### What does Centene Corporation do? Centene Corporation is a leading managed care organization (MCO) focused primarily on government-sponsored healthcare programs, serving uninsured and under-insured individuals. The company operates as a health insurer, collecting premiums from states and the federal government to manage the healthcare costs of its members. ### What are Centene's main revenue sources and business segments? Centene's primary revenue sources stem from its three main business segments: Medicaid, which accounts for approximately 55% of premium revenues, Commercial/Marketplace at about 25%, and Medicare at roughly 20%. The company generates revenue by collecting premiums from state and federal governments for managing healthcare services. ### How does Centene's working capital profile affect its cash flow? Centene typically exhibits a negative net working capital profile, which is characteristic of its managed care business model. This occurs because the company collects premiums upfront from payers and disburses medical claims later, creating a structural cash flow advantage known as 'float'. ### What is Centene's approach to capital expenditure? Centene's capital expenditure (Capex) as a percentage of revenue is relatively low, typically ranging from 0.5% to 1.0%. This Capex is predominantly allocated to growth initiatives, particularly in IT investments such as capitalized software for claims processing and digital member platforms. ### What is the primary purpose of the Centene Corporation financial model? The Centene Corporation financial model is designed to evaluate the company's equity valuation and earnings power. It enables analysts to forecast the normalization of the Health Benefits Ratio post-Medicaid redeterminations, assess the margin impact of the Value Creation Plan, and project membership growth across government-sponsored healthcare segments. ### Can I download an Excel financial model for Centene Corporation? Yes, an Excel financial model for Centene Corporation is available for download. This general corporate model provides a forecast horizon from FY2026 to FY2030, allowing for detailed financial analysis and scenario planning. [Interactive forecast calculator](https://finamodel.com/companies/centene/forecast)